NCT03541499: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03541499 |
|---|---|
| Title | A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 23, 2018 |
| Completion date | May 15, 2020 |
| Required reporting date | May 15, 2023, midnight |
| Actual reporting date | Nov. 24, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |